Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study

David S Alberts, S. P. Balcerzak, J. D. Bonnet, R. L. Stephens

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.

Original languageEnglish (US)
Pages (from-to)1321-1323
Number of pages3
JournalCancer Treatment Reports
Volume69
Issue number11
StatePublished - 1985

Fingerprint

Mitoxantrone
Multiple Myeloma
Leukopenia
Drug Combinations
Doxorubicin
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alberts, D. S., Balcerzak, S. P., Bonnet, J. D., & Stephens, R. L. (1985). Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study. Cancer Treatment Reports, 69(11), 1321-1323.

Phase II trial of mitoxantrone in multiple myeloma : A southwest oncology group study. / Alberts, David S; Balcerzak, S. P.; Bonnet, J. D.; Stephens, R. L.

In: Cancer Treatment Reports, Vol. 69, No. 11, 1985, p. 1321-1323.

Research output: Contribution to journalArticle

Alberts, DS, Balcerzak, SP, Bonnet, JD & Stephens, RL 1985, 'Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study', Cancer Treatment Reports, vol. 69, no. 11, pp. 1321-1323.
Alberts, David S ; Balcerzak, S. P. ; Bonnet, J. D. ; Stephens, R. L. / Phase II trial of mitoxantrone in multiple myeloma : A southwest oncology group study. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 11. pp. 1321-1323.
@article{d38cff0b30db4c1b8a8119478dc00f8b,
title = "Phase II trial of mitoxantrone in multiple myeloma: A southwest oncology group study",
abstract = "Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3{\%}) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11{\%}) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.",
author = "Alberts, {David S} and Balcerzak, {S. P.} and Bonnet, {J. D.} and Stephens, {R. L.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "1321--1323",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Phase II trial of mitoxantrone in multiple myeloma

T2 - A southwest oncology group study

AU - Alberts, David S

AU - Balcerzak, S. P.

AU - Bonnet, J. D.

AU - Stephens, R. L.

PY - 1985

Y1 - 1985

N2 - Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.

AB - Thirty-five fully evaluable patients with advanced multiple myeloma, refractory to standard chemotherapeutic agents, were entered into a phase II trial with mitoxantrone at a starting dose of 12 mg/m2 iv every 3 weeks. There was one (3%) partial response (lasting 2 1/2 months) in a patient who had received treatment with five different agents, including doxorubicin (total dose, 150 mg/m2). Four additional patients (11%) showed objective evidence of clinical improvement, lasting 4-7 months. Mitoxantrone was well-tolerated with no drug-induced deaths and only moderate to severe leukopenia as the dose-limiting toxicity in the majority of patients. Although mitoxantrone had a low level of activity in this heavily pretreated patient population, consideration should be given to future trials incorporating mitoxantrone into a new drug combination.

UR - http://www.scopus.com/inward/record.url?scp=0022406156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022406156&partnerID=8YFLogxK

M3 - Article

C2 - 4092195

AN - SCOPUS:0022406156

VL - 69

SP - 1321

EP - 1323

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -